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Introduction 
In the present chapter, we will review our studies of the potential role of tacro-
limus in xenotransplantation based largely on experiments in which rats were 
recipients of vascularized organs from either hamsters or mice. Because these 
xenografts after transplantation elicit a strong humoral response and are rejected 
within a few days, these models were considered until the last few years to be 
moderately difficult [1-10), more so than the sheep-to-goat combination of Per-
per and Najarian [n] or the wolf-to-dog model of Hammer et al. [12]. 
Hamster-to-Rat Model 
This model was added to the transplant research armamentarium by Clyde Bar-
ker and Rupert Billingham at the University of Pennsylvania [1]. However, 
16 years passed before significant progress was made in breaking down this xeno-
geneic barrier. Then, Knechtle et al. [13) reported extended survival of hamster 
hearts in rat recipients treated with total lymphoid irradiation followed by 
cyclosporine. However, a precise explanation for this limited success was not evi-
dent. The advent of tacrolimus, a more potent T cell-directed immunosuppressant 
[14-21] has permitted better insight into the m~chanisms of xenograft rejection 
in this model, especially when it has been combined with other agents that dis-
rupt the xenogeneic immune reaction at a different site. The use of such drug 
combinations has consistently led to indefinite survival in the hamster-to-rat 
and other closely related rodent organ xenotransplant models as will be 
described in the following pages. We will also discuss how these experiments 
have cast light on the mechanisms of xenograft rejection. 
Humoral Responses 
Using complement-dependent cytotoxicity assays, low titers (1:16-1:32) of pre-
formed anti-hamster cytotoxic antibodies have been demonstrated in the sera 
of naive Lewis rats (22). Isotyping studies using flow cytometric analysis invari-
ably reveal a greater preponderance of IgM rather than IgG antibodies. Rejection 
of liver xenografts is accompanied by astronomical elevations of antihamster 
cytotoxic antibodies and massive enlargement of the spleen in untreated recipi-
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ents [23). Within the spleen, this is associated with marked stimulation of 
IgM++ brightlIgD+ dull B cells, which in the rat are preferentially localized in the 
marginal zone and red pulp. Given its marked diminution following tacrolimus 
therapy, this response has appeared to be at least partially T cell dependent 
[22J. Nevertheless, the localization and phenotypic profile of the responding reci-
pient splenocytes also have suggested the involvement of a subpopulation of B 
cells which are mediators of a T-independent immune response [22, 24/. Since 
the host's primitive defense against blood-borne polysaccharide antigens is 
mediated by B cells of similar phenotype [25), it is therefore tempting to specu-
late that splenic IgM++ /IgD+ B cells in the rat studied by' Langer et al. (22) are 
analogues of human CD5+and mouse Ly 1+ B cell subsets [26/. These cells 
have also been implicated to playa seminal role in the generation of destructive 
xenoreactive antibodies in other models [27 j, although recent experiments by 
Pitre et al. [28) contradict this assumption. 
Fate of Different Organs 
Heart 
Hamster hearts are rejected by antibody-mediated mechanisms within 3-4 days 
[1-10). There is evidence for progressive platelet and fibrin deposition in the 
microvasculature and margination of neutrophils in larger vessels, with accompa-
nying endothelial cell hypertrophy and focal denudation. There is also evidence 
for increased deposition of IgM, IgG, and C3 in both the endothelium of the lar-
ger vessels and in that of the microvasculature [22). These events lead to wide-
spread hemorrhagic necrosis precipitating xenograft loss. The use of tacrolimus 
(1-2 mg/kg per day until rejection) alone does not significantly prolong graft sur-
vival nor does it alter the histopathological or immunofluorescence observations 
detailed above [5, 7, 22). It also fails to attenuate the gradually increasing xenos-
pecific cytotoxic antibody titers in the recipients lending further credence to ear-
lier contentions that the generation of xenoantibodies by a T cell-independent 
mechanism, along with complement, serve as main effectors in this model 
[29/. Further corroboration of this assertion is obtained when an increase in 
the titers of anti-hamster antibodies is noted in T cell-deficient nude rats receiv-
ing hamster heart xenografts [30-32). In addition, Van den Bogaerde et al. [29) 
have shown that inhibition of recipient complement by cobra venom factor 
results in prolonged survival of hamster heart xenografts only when combined 
with a T-cell immunosuppressant like cyclosporine, pointing out the duality of 
the humoral and cellular mechanisms of xenograft rejection. 
In an attempt to abate cardiac xenograft rejection, thereby prolonging survi-
val, Murase et al. [7J have also tested tacrolimus in combination with antimeta-
bolites such as cyclophosphamide, methotrexate, brequinar sodium (BQR) and 
RS-61443. Of the antimetabolites used, cyclophosphamide, a purine antimetabo-
lite with pronounced B cell specificity [33/, and BQR, which inhibits de novo pyr-
imidine [34/, consistently allow for protracted heart xenograft survival (Table I). 
More prolonged graft survival is witnessed when cyclophosphamide plus tacroli-
(, 
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mus immunosuppression therapy is used. Similarly, when RS-61443, a purine 
synthesis inhibitor [35], is used in combination with tacrolimus a dramatic pro-
longation in xenograft survival is observed [7]. When used alone, mizorbine. an 
inhibitor of purine synthesis [36), and deoxyspergualin (DSG), an analogue of the 
antitumor antibiotic spergualin [37], have no discernible effect on cardiac xeno-
graft survival, which is, however, prolonged with the addition of tacrolimus to 
the immunosuppressive regimen (Table 1). Methotrexate when used alone leads 
to modest prolongation of survival; however, when used in combination with 
tacrolimus results in indefinite graft survival. Interestingly, the use of tacrolimus 
alone in splenectomized recipients also results in indefinite survival of subse-
quently transplanted cardiac xenografts (38). 
Table 1. Survival of hamster heart, liver. and kidney xenografts in Lewis rats immunosuppressed 
with tacrolimus and anti proliferative agents 
Organ Treatment Dose (mg/kg per day) Median survival (days) 
Heart [7J None 3.0 
FK506 2.0 4.0 
BQR 4.5 >42.0 
RS-61443 40.0 7.0 
Cyclophosphamide 15.0 56.0 
Methotrexate 0.5 13.0 
Mizorbine 7.5 4.0 
DSG 5.0 4.0 
FK506 + BQR" 1.0 + 4.0 >100.0 
FK506 + RS-61443a 2.0 + 20.0 >100.0 
FK506 + cyclophosphamide" 2.0 + 7.5 >100.0 
FK506+methotrexatea 2.0 + 1.0 >100.0 
FK506 + mizorbine" 2.0 + 7.5 >52.5 
FK506 + DSGa 2.0 + 5.0 >100.0 
FK506 + cyclophosphamideb 2.0 + 80.0 >100.0 
Splenectomy [38J 5.0 
FKS06 + splenectomy [38) 2.0 >100.0 
Liver (7J None 7.0 
BQR 3.0 12.0 
RS-61443 20.0 7.0 
Cyclophosphamide" 7.5 9.0 
FK506 + BQRa 1.0 + 3.0 >100.0 
FKS06 + RS-61443" 1.0 + 20.0 >100.0 
FKS06 + cyclophosphamide" 1.0 + 7.5 >100.0 
FKS06 + cyclophosphamideb 1.0 + 80.0 >100.0 
Kidney (67) None 6.0 
FK506 2.0 6.0 
Cyclophosphamide 7.5 8.0 
FK506 + cyclophosphamide" 2.0 + 10.0 11.5 
FK506 + cyclophosphamide" 1.0 + 15.0 79.0 
BQR. brequinar sodium; DSG. deoxyspergualin. 
a Antimetabolites were given in either 14- or 30-day course. 
bCyc1ophosphamide was given as a single injection 10 days before organ transplantation. 
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Consistent with the findings of Kumararatne et al. [391. we also observed that 
a single dose of cyclophosphamide (500 mg/m" Lp.) results after 10 days in the 
depletion primarily of the IgM++ /IgD+ cells normally residing in the marginal 
zone of the spleen [221. To elucidate the role played by these B cells in xenograft 
rejection, hamster hearts were transplanted into rats with or without tacrolimus 
therapy 10 days after a single bolus injection of cyclophosphamide. Although 
slight prolongation of xenograft survival is observed in animals pretreated 
with cyclophosphamide alone, the addition of tacrolimus nevertheless results 
in indefinite graft survival (Table 1). These observations suggest that splenic B 
cells of this distinct phenotype may mediate an important effector function cul-
minating in xenograft rejection in this model. However, there is a T cell-mediated 
mechanism of graft injury which neither cyclophosphamide nor splenectomy, 
when used alone (23, 38, 40, 41), are able to attenuate. Accordingly, the use of 
strategies which allow for inhibition of both Band T cell function provides an 
optimal means to control xenograft rejection in this model [6, 71. 
liver 
Unlike heart xenografts, hamster livers are acutely rejected by untreated Lewis rat 
recipients in 7 days by a composite humoral and cell-mediated immunity [5, 7. 22, 
231. The early deposition of anti-hamster antibodies in the sinusoids and portal 
tracts is followed by cellular infiltration in these areas composed largely of reci-
pient CDS+ T and few natural killer cells. This histopathological finding differs 
from that witnessed during liver allograft rejection, where the initial cellular 
infiltrate is localized primarily in the portal or perivenular areas [421. These find-
ings provide support for a role of antibody-mediated cellular cytotoxicity in 
xenograft rejection [43-451. When tacrolimus is used alone, it significantly pro-
longs xenograft survival with 10 %-30 % of the recipients surviving indefinitely 
[5, 7, 461. Single drug therapy using either BQR, RS-61443 or cyclophosphamide 
has minimal impact on graft survival, whereas the addition of tacrolimus to 
BQR, RS-61443, or cyclophosphamide-treated recipients leads to their indefinite 
survival (Table 1). As with hearts, pretreatment of liver xenograft recipients 
with a single bolus injection of cyclophosphamide 10 days prior to organ trans-
plantation also results in their indefinite survival (Table 1) [7, 221. 
Despite its moderate efficacy in prolonging liver xenograft survival, tacroli-
mus when used alone does not mitigate the extreme elevation of xenospecific 
cytotoxic antibody titers in the recipient serum, which reach a peak around 
day 7 post-transplantation. However, by day 30 post-transplantation, these anti-
bodies become undetectable in tacrolimus-treated recipients, the majority of 
whom nevertheless succumb to late graft failure subsequent to biliary obstruc-
tion [221. We have hypothesized that this outcome represents a delayed manifes-
tation of humoral injury which may have transpired early during the period fol-
lowing transplantation [471. This assertion is further substantiated by the 
obvious lack of biliary complications and long-term survival of tacrolimus-trea-
ted recipients who had received a short perioperative course of BQR or RS-61443; 
both of which are known to partially abate the initial peak antibody response 
[71. 
. , 
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Although tacrolimus does not have an effect on xenoantibody production when 
therapy starts on the day of transplantation, Tsugita et al. [48] have shown that 
this immunosuppressant not only abrogates the hyperacute liver xenograft rejec-
tion induced by pretransplant infusion of hamster hepatocytes or liver nonpar-
enchymal cells (NPC, which include liver sinusoidal cells), but also prolongs 
graft survival beyond that achieved by pretransplant treatment with tacrolimus 
alone. The interesting observation is that, although the cytotoxicity (IgM) of 
the recipient's serum against hamster lymphocytes remains high despite tacroli-
mus therapy, that against hamster-specific NPC is blunted. Similarly, we have 
shown recently that T cell-deficient nude rats that receive hamster whole blood 
1 week prior to transplantation with a hamster heart never reject the graft in a 
hyperacute fashion. Indeed, the heart xenografts survive indefinitely in most of 
the cases [49]. These observations indicate the importance of T cell help in the 
induction of xenosensitization and hyperacute rejection in this xenograft model. 
Our achievement of long-term survival in liver xenograft recipients has 
afforded us the opportunity to study several physiological and immunological 
features uniquely associated with this organ. We have specifically investigated 
the metabolic and coagulatory changes [50, 51] that occur in the liver xenograft 
recipients and the cellular events that lead to the induction of donor-specific tol-
erance [46]. Rats who accept hamster liver xenografts exhibit species-specific 
unresponsiveness to subsequently transplanted donor organs. It must be empha-
sized that while they retain donor-specific tolerance, the liver recipients are fully 
capable of rejecting organs from other animal species [46]. 
This species-specific immunological unresponsiveness, afforded best by the 
liver but also witnessed after heart xenotransplantation as reported by Tanaka 
et al. [52], may be ascribed to the establishment of chimerism, which has been 
shown to play a seminal role in the induction of donor-specific tolerance [53-
56]. Additionally, it is also well known that given their species-specific restric-
tion. certain membrane-associated complement (C) regulatory proteins. such as 
decay-accelerating factor (DAF), membrane cofactor protein (MCP), and CD59 
antigen, among others. play an important role in protecting autologous or homo-
logous tissues from collateral damage that may be prompted by C activation [57-
62]. Therefore. the production by the liver of species-specific circulating C pro-
teins may provide yet another mechanism by which this organ may exert its 
observed protective effects. 
Further credence to the latter hypothesis is provided by exhaustive experi-
ments in rats in which species-specific tolerance is successfully achieved by 
prior hamster liver xenotransplantation [63, 64]. The intravenous administration 
of C-depleted (but not enriched) rat anti-hamster hyperimmune serum into these 
tolerant animals has no deleterious effect on simultaneously transplanted hamster 
hearts which enjoy prolonged survival. These observations underscore the perni-
cious nature of heterologous C which, following xenotransplantation of organs 
other than livers. may play a major role in mediating the antibody-dependent 
rejection [65]. In view of this it would be reasonable to predict that clinical trans-
plantation of organs, other than livers. from transgenic pigs expressing human C 
regulatory proteins on their endothelium would prevent hyperacute rejection as 
has already been demonstrated by White et al. [66]. Of concern, however. is 
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the potential risk to the liver recipient of heterologous C secreted by the xeno-
grafted organ, whose uninhibited activity may precipitate an autoimmune-like 
syndrome. This is an area of research which warrants further investigation. 
Kidney 
Similar to our observations for hearts, Miyazawa et al. [67] have reported that 
hamster kidney xenografts are rejected by untreated rat recipients in 5-6 days 
predominantly by a humoral response. The use of tacrolimus alone does not pro-
long graft survival nor has any appreciable effect on the generation of rat anti-
hamster IgM antibodies. Although the additional use of cyclophosphamide 
along with tacrolimus extends xenograft survival, the results are not as dramatic 
and consistent as those obtained with heart and liver xenografts (Table 1). 
Attempts to deplete heterospecific antibodies by pre-transplant perfusion of reci-
pient'S blood through donor-strain kidneys or livers, as well as the use of the 
anti-complementary agent K76 [68.69], result in marginal prolongation of survi-
val of subsequently transplanted kidney xenografts in tacrolimus/cyclophospha-
mide-treated rat recipients (Table 1). Interestingly, Ye et al. [70j have observed 
that the majority of kidney xenograft recipients develop severe polyuria which 
is not corrected by restriction of water intake. Since the minimal histopathologi-
cal changes in the kidney xenografts cannot account for the de novo development 
of diabetes insipidus witnessed in this model, it is speculated that there might be 
a functional incompatibility between transporter proteins expressed on cells in 
hamster kidney with that of their ligands in the rats. Attempts are underway 
to provide substantial evidence for the latter postulate. 
Mouse-to-Rat Model 
Similar to our observations in the hamster-to-rat model, mouse hearts when 
transplanted into unmodified rat recipients are rejected by antibody-mediated 
mechanisms within 2-3 days [71-73]. However, Pan et aJ. [73] have shown that 
liver xenografts when transplanted into untreated Lewis rats survive for approxi-
mately 7 days, succumbing eventually to combined antibody and cell-mediated 
rejection (Table 2). Although no appreciable difference in mouse heart xenograft 
Table 2. Survival of BIO.BR mouse hearts and livers xenografted into Lewis rat recipients with or 
without tacrolimus immunosuppressive therapy 
Organ Tacrolimus Graft survival (days) Median survival (days) 
Heart No 2. 2. 2. 2, 2, 2. 3. 3 2.7=:1.7 
Heart' Yes 2. 2. 3, 3. 3 2.8±0.8 
Liver No 7. 7, 7. 7. 7 7.0 
Liverb Yes 18,18.28,37,61, 82, 93,107,110, Ill, 103.9±64.7 
117,133,203,207.221 
:1 mg/kg per day, i.m. 
I mg/kg per day x 30 days followed by 0.5 mg/kg every other day for the next 70 days. 
n 
-' 
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survival is observed following tacrolimus administration. it does however. 
improve the outcome in mouse liver graft recipients. 50 % surviving beyond 
100 days. Despite the presence of elevated xenospecific antibodies. the observa-
tion of long-term liver xenograft survival in this model further emphasizes the 
inherent resistance of this organ to antibody-mediated injury. The donor-specific 
protective effect afforded by the transplanted liver following hamster-to-rat xeno-
transplantation is also witnessed in this model. This effect appears to be species-
specific but non-major histocompatibility complex (MHC) restricted. allowing 
for transplanted mouse hearts obtained from donors of varying MHC phenotype 
to be equally protected. whereas hearts obtained from hamster are promptly 
rejected [74]. 
Comment 
Our studies have demonstrated that the interdiction of the initial B cell prolifera-
tive response is the critical first step towards successful xenotransplantation in 
closely related species. Once the antibody barrier is breached. the need for the 
antiproliferative drugs apparently diminishes with tacrolimus-based monotherapy 
being sufficient to maintain graft function. The manipulation of the donor andl 
or the recipient with novel agents such as phosphatidic acid inhibitors [75] and 
the creation of chimeric donors [76. 77] are some of the more contemporary 
approaches that are currently being employed in our laboratory to make xeno-
transplantation a clinical reality. 
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